Friday, May 1, 2026

Kim Jong Un’s Urgent Directive: North Korea’s Race to Complete Local Factory Projects by Year-End

Kim Jong Un inspects a local factory construction in North Korea, emphasizing timely completion and the importance of the 20×10 Development Policy.

U.S. Oil Prices Surge: What It Means for Asian Markets in 2026

U.S. index futures drop as oil prices rise, influenced by allies' reluctance to deploy troops, causing market concerns.

Wantech Targets U.S. Market Expansion at AAD 2026: Key Strategies Revealed

Wontech aims to expand in the U.S. by showcasing products at the AAD and hosting Wave Denver 2026 for healthcare partnerships.

Tag: obesity treatment

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

HK inno.N partners with Atomatrix to co-develop AI-based next-generation obesity drug

HK inno.N partners with Atomatrix to develop AI-driven obesity treatments, focusing on novel small-molecule candidates.

Mounjaro prescriptions surge 12-fold in 8 months, surpassing 200,000 monthly for the first time

Mounjaro prescriptions surged over tenfold in eight months, raising concerns about access for patients with obesity amid rising cosmetic demand.

Metabia Begins Dosing First Patient in Phase 1 Part 3 Trial of Obesity Drug DA-1726

Metabia begins Phase 1 trial for DA-1726, a dual-action obesity treatment, aiming for safety and efficacy in weight loss by 2026.

DA-1726: The New Dual-Action Obesity Treatment Set to Transform Weight Loss in 2026

MetaVia's DA-1726 obesity treatment trial approved by U.S. IRB, focusing on dual-action GLP-1 and Glucagon receptors for weight loss.

Unlocking Weight Loss: How Celltrion’s New CT-G32 and Oral Multi-Action Drug Will Change the Game

Celltrion aims to lead the obesity treatment market with innovative drugs, enhancing efficacy and patient convenience through dual approaches.

Why Are Weight-Loss Drugs So Much Pricier in South Korea?

South Korea faces high obesity treatment costs compared to China and Japan, with no insurance coverage, despite potential patent expirations.

Unlocking Weight Loss: Hanmi Pharmaceutical’s Innovative H.O.P Project and the Game-Changing Epaglenatide

Hanmi Pharmaceutical is innovating obesity treatment with efpeglenatide and HM15275, focusing on tailored solutions for Korean patients.

HM15275 Clinical Trials: What You Need to Know About This Groundbreaking Obesity Treatment

Hanmi Pharmaceutical's HM15275 enters Phase 2 trial, aiming to revolutionize obesity treatment and diabetes management by 2030.

Novo Nordisk’s Oral Wegovy Tops 3,000 Prescriptions in Its First Week—A Challenge to Injectable GLP-1s

Novo Nordisk's Wegovy oral treatment exceeds 3,000 prescriptions in its debut week, signaling a shift towards oral obesity medications.

Weight-Loss Drugs Could Cut Airline Fuel Bills by $580 Million—An Unexpected Win for U.S. Carriers

The obesity treatment market is growing, helping U.S. airlines save on fuel costs due to decreased passenger weight.

Patches, Implants, and Oral Films… The Drug-Delivery Format Battle After Oral Wegovy

Oral Wegovy's launch is transforming obesity treatment, focusing on user-friendly delivery methods and enhancing patient adherence.

Is RPG-102 the Future of Obesity Treatment? Discover the Breakthrough Oral Solution!

ProGen and Rani Therapeutics initiate a Phase 1 trial for RPG-102, an oral obesity treatment, aiming for effective weight loss with weekly dosing.

New Obesity Pill Could End Wegovy’s Reign, Offering Faster and Safer Results

Ildong's ID110521156 shows promise as an affordable GLP-1 obesity drug with fewer side effects, aiming to transform the treatment landscape.

Wegovy Gets Stronger: New Dose Promises Even More Weight Loss

Novo Nordisk's new high-dose Wegovy aims to enhance obesity treatment, with promising trial results and a strategic EU rollout planned.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.